The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Castle Biosciences, Inc(NASDAQ:CSTL) 
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melano...
Website: http://www.castlebiosciences.com
Founded: 2007
IPO Price: $16 (Jul 25, 2019)
Full Time Employees: 133
CEO: Derek J. Maetzold
Sector: Healthcare
Industry: Diagnostics & Research
Castle Biosciences Days Payable Outstanding ttm (DPO)
Castle Biosciences Days Receivable Outstanding ttm (DSO)
Castle Biosciences Days Inventory Outstanding ttm (DIO)
Castle Biosciences Op Cashflow Per Share ttm
Castle Biosciences Free Cashflow Per Share ttm
Castle Biosciences Cash Per Share ttm
Castle Biosciences P/S ratio ttm
Castle Biosciences (GAAP) P/E ratio ttm
Castle Biosciences P/B ratio ttm
No extra charts and metrics for this ticker.